Replies to post #144256 on Biotech Values

[DewDiligence]

Xarelto + antiplatelet drug improved post-STEMI survival by more than antiplatelet drug alone:

http://www.bloomberg.com/news/2012-08-27/bayer-s-xarelto-helped-survival-after-heart-attack-study.html

The 7,817 patients studied had a more serious type of heart attack that is typically caused by a blood clot completely blocking the coronary artery, leading to damage and the death of heart muscle. The treatment period was 24 months.

The SoC for STEMI treatment is an antiplatelet drug alone without an anticoagulant, so this is a pretty significant and surprising finding.

Paradoxically, Xarelto was recently rejected by the FDA as a treatment for ACS (#msg-76856261); it is still being considered such this indication in the EU.